-
Fierce Pharma Asia—Takeda R&D chief's new strategy; AZ, Daiichi's ADC nod; Fosun's failed Henlius buy
24 Jan 2025 20:54 GMT
… majority shareholder Fosun Pharma’s take-private proposal. … China’s Ascentage Pharma filed for an IPO on the Nasdaq … Biokin Pharmaceutical and Shanghai Bao Pharmaceuticals, filed for Hong Kong IPOs.
5 … its Advanced Therapies unit, WuXi AppTec has decided to …
-
StockWatch: Illumina Tumbles on Q4 Results, China Retaliation
08 Feb 2025 21:43 GMT
… two other companies: WuXi AppTec (2359.HK) and WuXi Biologics (2269.HK … of the UK Biobank’s Pharma Proteomics Project —which they launched … day of trading, from the initial public offering (IPO) price of $18 to $25 … ,234 additional shares at the IPO price.
-
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
10 Jan 2025 16:17 GMT
… ’s Japanese unit Chugai Pharmaceutical is teaming up with … vaccines plant from CDMO WuXi Biologics
WuXi Biologics has decided to … preclinical trispecific candidate from WuXi Biologics. The company is … Biosciences files for $397M IPO amid expansion efforts
11. …
-
HUHUTECH International Group Inc. Announces Closing of Initial Public Offering
23 Oct 2024 20:30 GMT
Wuxi, China, Oct. 23, 2024 (GLOBE … announced the closing of its initial public offering (the “Offering”) of 1,050 … system in the Company’s Wuxi plant; (ii) the expansion and … factories, as well as some pharmaceutical, food and beverage manufacturers. For …
-
HUHUTECH International Group Inc. Announces Pricing of Initial Public Offering
21 Oct 2024 22:00 GMT
Wuxi, China, Oct. 21, 2024 (GLOBE … announced the pricing of its initial public offering (the “Offering”) of 1,050 … system in the Company’s Wuxi plant; (ii) the expansion and … factories, as well as some pharmaceutical, food and beverage manufacturers. For …
-
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
05 Feb 2025 12:05 GMT
… an upsized Series C and initial public offering, raising approximately $458.7 million … , including from large and specialty pharmaceutical and biotechnology companies, many of … drug substance and drug product, WuXi Biologics (Hong Kong) Limited, which …
-
HUHUTECH International Aims For U.S. IPO At Ultra-High Valuation
04 Sep 2024 18:30 GMT
… factories, as well as some pharmaceutical, food and beverage manufacturers.… gas supply system in our Wuxi plant; approximately 30% of … seeking a U.S. IPO. Regarding outstanding legal proceedings, … , aiming their IPOs at retail investors. Post-IPO, the vast …
-
Ascentage Pharma Announces 2024 Interim Results
22 Aug 2024 17:09 GMT
… Inner Mongolia Autonomous Region, Wuxi, Huzhou, Shenzhen, and Yantai, … initial public offering of American depositary shares (ADSs) representing its ordinary shares. Ascentage Pharma … investors." About Ascentage Pharma Ascentage Pharma (6855.HK) is a …
-
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
06 Aug 2024 14:50 GMT
… speculative in nature, such as pharmaceuticals and biotechnology. In a … than 34% from its 2019 initial public offering (IPO) share price. It is … with Brii Biosciences, Alnylam Pharmaceuticals, MedImmune, WuXi Biologics, Glaxo Wellcome, GlaxoSmithKline …
-
Fierce Pharma Asia—AbbVie's TL1A deal; Ex-Takeda staffer's guilty plea; Kyowa Kirin's $530M plant investment
14 Jun 2024 13:18 GMT
… from defense spending bill
WuXi AppTec and WuXi Biologics got a temporary … drugs.
7. Alumis sets out IPO ambitions to fund TYK2 inhibitor …
Alumis is looking for an IPO to accelerate the development of … -licensed from China’s Haisco Pharma back in 2021 for up …